Medigene's Drug Veregen® Obtains Market Approval In Switzerland
(Thomson Reuters ONE) -
MediGene AG /
Medigene's Drug Veregen® Obtains Market Approval In Switzerland
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Market launch planned during 2012
Martinsried/Munich, March 30, 2012. MediGene AG (MDG, Frankfurt, Prime Standard)
announced today that Veregen(®) for the treatment of genital warts has obtained
market approval in Switzerland. Market launch of Veregen(®) by Medigene's
partner Abbott is scheduled to take place during 2012, upon conclusion of the
reimbursable price-fixing procedure by the responsible authority Swissmedic.
Veregen(®) is currently available on the US, German, and Austrian markets.
Market launch in Spain is in preparation. In addition, marketing authorization
applications for an additional 17 European countries were assessed positively by
the regulatory authorities in March 2012. Medigene expects that the national
marketing authorizations will be formally granted by the respective regulatory
authorities within the next few months.
Medigene has entered into several marketing partnerships for Veregen(®),
including Fougera (formerly Nycomed) for the United States; Abbott for Germany,
Austria, and Switzerland; Laboratoires Expanscience for France; and a number of
other partners across Europe, America, and Asia. Medigene is planning to
continue this global licensing strategy.
Veregen(®): Veregen(®) (previously Polyphenon E(®) ointment), a topical
treatment for external genital warts, contains a concentrate of catechins with a
complex defined composition extracted from green tea leaves. Medigene acquired
the basic rights to the active ingredient in Veregen(®) from Epitome
Pharmaceuticals, Inc. in 1999, and was solely responsible for the drug's
successful preclinical and clinical development, as well as the approval
process. Sinecatechins 15% ointment (Veregen(®)) is recommended in the US
Department of Health and Human Services Center for Disease Control and
Prevention's Sexually Transmitted Diseases Treatment Guidelines 2010 as a
possible option for treating genital warts.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(® )and Veregen(®) are registered trademarks of MediGene AG. Polyphenon
E(® )is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
- End -
MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to have revenues from
marketed products, which are distributed by partner companies. It has two drug
candidates in clinical trials and is developing an innovative vaccine
technology.
Contact
Julia Hofmann & Kerstin Langlotz
Tel.: +49 - 89 - 85 65 - 33 01
Fax: +49 - 89 - 85 65 - 29 20
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
press release as pdf:
http://hugin.info/132073/R/1598454/504036.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MediGene AG via Thomson Reuters ONE
[HUG#1598454]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.03.2012 - 01:31 Uhr
Sprache: Deutsch
News-ID 1098202
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried / München
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 86 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene's Drug Veregen® Obtains Market Approval In Switzerland
"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
